Recombinant multi-species A2ML1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine A2ML1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a member of the alpha-macroglobulin superfamily. The encoded protein is thought to be an N-glycosylated monomeric protein that acts as an inhibitor of several proteases. It has been shown to form covalent interactions with proteases, and has been reported as the p170 antigen recognized by autoantibodies in the autoimmune disease paraneoplastic pemphigus (PNP; PMID:20805888). Mutations in these gene have also been associated with some cases of Noonan syndrome (NS; PMID:24939586) as well as some cases of otitis media (PMID:26121085). Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Aug 2015]
The Alternative Names of target: A2ML1,Alpha-2-macroglobulin-like protein 1,C3 and PZP-like alpha-2-macroglobulin domain-containing protein 9,CPAMD9,OMS,p170

Target products collectionGo to A2ML1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-SE0631-Ag-1/ GM-Tg-hg-SE0631-Ag-2 Human A2ML1 protein Human
GM-Tg-rg-SE0631-Ag-1/ GM-Tg-rg-SE0631-Ag-2 Rat A2ML1 protein Rat
GM-Tg-mg-SE0631-Ag-1/ GM-Tg-mg-SE0631-Ag-2 Mouse A2ML1 protein Mouse
GM-Tg-cynog-SE0631-Ag-1/ GM-Tg-cynog-SE0631-Ag-2 Cynomolgus/Rhesus macaque A2ML1 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-SE0631-Ag-1/ GM-Tg-felg-SE0631-Ag-2 Feline A2ML1 protein Feline
GM-Tg-cang-SE0631-Ag-1/ GM-Tg-cang-SE0631-Ag-2 Canine A2ML1 protein Canine
GM-Tg-bovg-SE0631-Ag-1/ GM-Tg-bovg-SE0631-Ag-2 Bovine A2ML1 protein Bovine
GM-Tg-equg-SE0631-Ag-1/ GM-Tg-equg-SE0631-Ag-2 Equine A2ML1 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-SE0631-Ag-1/ GM-Tg-hg-SE0631-Ag-2; GM-Tg-rg-SE0631-Ag-1/ GM-Tg-rg-SE0631-Ag-2;
GM-Tg-mg-SE0631-Ag-1/ GM-Tg-mg-SE0631-Ag-2; GM-Tg-cynog-SE0631-Ag-1/ GM-Tg-cynog-SE0631-Ag-2;
GM-Tg-felg-SE0631-Ag-1/ GM-Tg-felg-SE0631-Ag-2; GM-Tg-cang-SE0631-Ag-1/ GM-Tg-cang-SE0631-Ag-2;
GM-Tg-bovg-SE0631-Ag-1/ GM-Tg-bovg-SE0631-Ag-2; GM-Tg-equg-SE0631-Ag-1/ GM-Tg-equg-SE0631-Ag-2
Products Name A2ML1 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name A2ML1
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine A2ML1 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.